Report of the 2nd " French Clinical Vaccinology Meeting Jean-Gerard Guillet": Immunization and respiratory diseases

Vaccine

Volumn 28, Issue 40, 2010, Pages 6551-6555

  Loulergue, P ^a   Burgel, P R ^b   Carrat, F ^c   Fritzell, B ^d   Guthmann, J P ^e   Locht, C ^f   Power, U F ^g   Varon, E ^h   Dusser, D ^c   Launay, O ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Early Development and Clinical Pharmacology   (France)

^e INSTITUT DE VEILLE SANITAIRE   (France)

^f UNIV LILLE   (France)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Influenza; Pneumococcal conjugate vaccine; Respiratory diseases; Tuberculosis; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; BCG VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; INFLUENZA VACCINE; PALIVIZUMAB; PENICILLIN G; PNEUMOCOCCAL CONJUGATE VACCINE 13; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; PNEUMOCOCCUS VACCINE; PROTEIN CONJUGATE VACCINE 7; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC THERAPY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS INFECTION; HUMAN; IMMUNIZATION; INCIDENCE; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; PANDEMIC INFLUENZA; PENICILLIN NON SUSCEPTIBLE STREPTOCOCCUS PNEUMONIA; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PULMONOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; STREPTOCOCCUS PNEUMONIA; TUBERCULOSIS;

EID: 77956416886     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.038     Document Type: Conference Paper

References (44)

1. Loulergue P., Launay O. Introduction to the First Clinical Vaccinology Meeting " Jean-Gerard Guillet" J Clin Virol 2009, 46(3):201.
2. GINA, Report. Global strategy for asthma management and prevention (updated 2009), ; 2009. http://www.ginasthma.com/.
3. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555.
4. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001, 345(21):1529-1536.
5. Nichol K.L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999, 130(5):397-403.
6. Wongsurakiat P., Maranetra K.N., Wasi C., Kositanont U., Dejsomritrutai W., Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004, 125(6):2011-2020.
7. Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006, (1):CD002733.
8. Bueving H.J., Bernsen R.M., de Jongste J.C., van Suijlekom-Smit L.W., Rimmelzwaan G.F., Osterhaus A.D., et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 2004, 169(4):488-493.
9. Cates C.J., Jefferson T.O., Rowe B.H. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2008, (2):CD000364.
10. Dransfield M.T., Nahm M.H., Han M.K., Harnden S., Criner G.J., Martinez F.J., et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180(6):499-505.
11. Varon E., Gutmann L. National reference centre for pneumococci; 2008 activities report, 2007 epidemiology 2009, Centre National de Référence des Pneumocoques, Paris, [In French]. http://wwwinvssantefr/surveillance/cnr/rapport_cnr_pneumo_2008pdf.
12. Sabuncu E., David J., Bernede-Bauduin C., Pepin S., Leroy M., Boelle P.Y., et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009, 6(6):e1000084.
13. Gaudelus J., Cohen R., Hovart J. Vaccine coverage with the heptavalent pneumococcal conjugate vaccine in 2007. Comparison with previous years and other paediatric vaccines: analysis of vaccination booklets. Med Enfance 2007, 27(5):1-4. [In French].
14. Institut de Veille Sanitaire. Le réseau EPIBAC, Surveillance des infections invasives à pneumocoques: Point essentiel en 2007, ; 2009 [In French]. http://wwwinvssantefr/surveillance/indexhtm.
15. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
16. ESAC. European surveillance of antimicrobial consumption, ; 2008. http://www.esac.ua.ac.be/.
17. Cohen R., Levy C., Bonnet E., Grondin S., Desvignes V., Lecuyer A., et al. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2010, 28:6114-6121.
18. World Health Organization 23-Valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rep 2008, 83(42):373-384.
19. Schenkein J.G., Park S., Nahm M.H. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008, 26(43):5521-5526.
20. de Roux A., Schmole-Thoma B., Siber G.R., Hackell J.G., Kuhnke A., Ahlers N., et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008, 46(7):1015-1023.
21. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(9):258-261.
22. Call S.A., Vollenweider M.A., Hornung C.A., Simel D.L., McKinney W.P. Does this patient have influenza?. JAMA 2005, 293(8):987-997.
23. Carrat F., Vergu E., Ferguson N.M., Lemaitre M., Cauchemez S., Leach S., et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008, 167(7):775-785.
24. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25(39-40):6852-6862.
25. Nichol K.L., Nordin J.D., Nelson D.B., Mullooly J.P., Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357(14):1373-1381.
26. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007, 7(10):658-666.
27. Demicheli V., Di Pietrantonj C. Peer review for improving the quality of grant applications. Cochrane Database Syst Rev 2007, 2:MR000003.
28. Jefferson T., Smith S., Demicheli V., Harnden A., Rivetti A., Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005, 365(9461):773-780.
29. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9(8):493-504.
30. Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev; 2010;2:CD005187.
31. Bruhl D.L., Paty M.C., Antoine D., Bessette D. Recent changes in tuberculosis control and BCG vaccination policy in France. Euro Surveill 2007, 12(9). E070913 3.
32. Guthmann J.P., de La Rocque F., Boucherat M., van Cauteren D., Fonteneau L., Lecuyer A., et al. BCG vaccine coverage in private medical practice: First data in children below two years old, seven months after the end of compulsory vaccination in France. Arch Pediatr 2009, 16(5):489-495.
33. Guthmann J.P., Fonteneau L., Antoine D., Cohen R., Levy-Bruhl D., Che D. Couverture vaccinale BCG et épidémiologie de la tuberculose chez l'enfant: où en est-on un an après la levée de l'obligation vaccinale en France?. Bull Epidemiol Hebd 2009, 12-13:113-116.
34. Calmette A., Guerin C., Negre L., Boquet A. Prémunition des nouveaux-nés contre la tuberculose par le vaccin BCG (1921 à 1926). Ann Inst Pasteur 1926, 40:89-133.
35. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis Meta-analysis of the published literature. JAMA 1994, 271(9):698-702.
36. Rodrigues L.C., Pereira S.M., Cunha S.S., Genser B., Ichihara M.Y., de Brito S.C., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366(9493):1290-1295.
37. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115(9):2472-2479.
38. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24(17):3408-3419.
39. Rouanet C., Debrie A.S., Lecher S., Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 2009, 11(13):995-1001.
40. Stensballe L.G., Ravn H., Kristensen K., Agerskov K., Meakins T., Aaby P., et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2009, 123(2):398-403.
41. Faldella G, Alessandroni R, Aquilano G, Vandini S, Lanari M, Silvestri M, et al. Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab. J Chemother; 2010;22(1):30-5.
42. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998, 102(3 Pt 1):531-537.
43. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005, 191(7):1093-1104.
44. Power U.F. Respiratory syncytial virus (RSV) vaccines-two steps back for one leap forward. J Clin Virol 2008, 41(1):38-44.